Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-4-6
pubmed:abstractText
Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors. For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies. IVIG now represents a standard therapeutic option for most antibody deficiencies. Routinely, IVIG is used in patients with X-linked agammaglobulinaemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class deficiency. In addition, IVIG is used extensively in the treatment of a wide variety of autoimmune disorders. IVIG is administered at distinct doses in the two clinical settings: whereas immunodeficient patients are treated with replacement levels of IVIG, patients with autoimmune and inflammatory diseases are administered with very high doses of IVIG. Several lines of experimental evidence gathered in the recent years suggest that the therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active role for IVIG, rather than a mere passive transfer of antibodies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1365-2249
pubmed:author
pubmed:copyrightInfo
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.
pubmed:issnType
Electronic
pubmed:volume
164 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2-5
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.
pubmed:affiliation
Institut National de la Santé et de la Recherche Médicale Unité 872, Paris, France. srini.kaveri@crc.jussieu.fr
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't